Singapore
September 9–10, 2025Marina Bay SandsDigital Partnering | September 16–17, 2025
Hu PingshengChairman & CEO at Guizhou Sinorda Biotechnology Co.,LtdPresenter
Profile
Sinorda was founded in 2010, and the headquarter was established in Guiyang,Guizhou. The company is focusing on drug development for digestive diseases and cell immunotherapy in digestive cancers. Linaprazan Glurate (X842 or SND001) is a PCAB for treatment of gastric acid related diseases that has been approved in China 2024 and will be launched in market this year. several other pipelines have entered the clinical stages, such as SND002 , a T cell injection and bispecific antibodies for treatment of IBD and other autoimmune diseases.
Agenda Sessions
Drug Discovery and Development: Guizhou Sinorda Biotechnology Co.,Ltd
, 11:45View Session